[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.169.76. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Platt  OS, Brambilla  DJ, Rosse  WF,  et al.  Mortality in sickle cell disease: life expectancy and risk factors for early death.  N Engl J Med. 1994;330(23):1639-1644. doi:10.1056/NEJM199406093302303PubMedGoogle ScholarCrossref
2.
Smith  WR.  Treating pain in sickle cell disease with opioids: clinical advances, ethical pitfalls.  J Law Med Ethics. 2014;42(2):139-146. doi:10.1111/jlme.12129PubMedGoogle ScholarCrossref
3.
Dowell  D, Haegerich  TM, Chou  R.  CDC guideline for prescribing opioids for chronic pain—United States, 2016.  JAMA. 2016;315(15):1624-1645. doi:10.1001/jama.2016.1464PubMedGoogle ScholarCrossref
4.
Cantrill  SV, Brown  MD, Carlisle  RJ,  et al; American College of Emergency Physicians Opioid Guideline Writing Panel.  Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department.  Ann Emerg Med. 2012;60(4):499-525. doi:10.1016/j.annemergmed.2012.06.013PubMedGoogle ScholarCrossref
5.
Johnson  K, Jones  C, Compton  W,  et al.  Federal response to the opioid crisis.  Curr HIV/AIDS Rep. 2018;15(4):293-301. doi:10.1007/s11904-018-0398-8PubMedGoogle ScholarCrossref
6.
Bohnert  ASB, Guy  GP  Jr, Losby  JL.  Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention’s 2016 opioid guideline.  Ann Intern Med. 2018;169(6):367-375. doi:10.7326/M18-1243PubMedGoogle ScholarCrossref
7.
Crowley-Matoka  M.  How to parse the protective, the punitive and the prejudicial in chronic opioid therapy?  Pain. 2013;154(1):5-6. doi:10.1016/j.pain.2012.10.013PubMedGoogle ScholarCrossref
8.
Brousseau  DCA, Panepinto  JA, Nimmer  M, Hoffmann  RG.  The number of people with sickle-cell disease in the United States: national and state estimates.  Am J Hematol. 2010;85(1):77-78.PubMedGoogle Scholar
9.
Tong  A, Sainsbury  P, Craig  J.  Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups.  Int J Qual Health Care. 2007;19(6):349-357. doi:10.1093/intqhc/mzm042PubMedGoogle ScholarCrossref
10.
Strauss  A, Corbin  J.  Basics of Qualitative Research Techniques. London, England: Sage Publications; 1998.
11.
Vaismoradi  M, Turunen  H, Bondas  T.  Content analysis and thematic analysis: implications for conducting a qualitative descriptive study.  Nurs Health Sci. 2013;15(3):398-405. doi:10.1111/nhs.12048PubMedGoogle ScholarCrossref
12.
Miller  J, Glassner  B. The ‘inside’ and the ’outside’: finding realities in interviews. In: Silverman  D, ed.  Qualitative Research: Theory, Method and Practice. London, England: Sage Publications; 1997:99-112.
13.
Holdstein  JA, Gubrium  JF. Active interviewing. In: Silverman  D, ed.  Qualitative Research: Theory, Method and Practice.  London, England: Sage Publications; 1997:113-129.
14.
Crouch  M, McKenzie  H.  The logic of small samples in interview-based qualitative research.  Soc Sci Inf (Paris). 2006;45(4):483-499. doi:10.1177/0539018406069584Google ScholarCrossref
15.
Treadwell  MJ, Hassell  K, Levine  R, Keller  S.  Adult sickle cell quality-of-life measurement information system (ASCQ-Me): conceptual model based on review of the literature and formative research.  Clin J Pain. 2014;30(10):902-914. doi:10.1097/AJP.0000000000000054PubMedGoogle ScholarCrossref
16.
Pack-Mabien  A, Labbe  E, Herbert  D, Haynes  J  Jr.  Nurses’ attitudes and practices in sickle cell pain management.  Appl Nurs Res. 2001;14(4):187-192. doi:10.1053/apnr.2001.26783PubMedGoogle ScholarCrossref
17.
Shapiro  BS, Benjamin  LJ, Payne  R, Heidrich  G.  Sickle cell-related pain: perceptions of medical practitioners.  J Pain Symptom Manage. 1997;14(3):168-174. doi:10.1016/S0885-3924(97)00019-5PubMedGoogle ScholarCrossref
18.
Labbé  E, Herbert  D, Haynes  J.  Physicians’ attitude and practices in sickle cell disease pain management.  J Palliat Care. 2005;21(4):246-251. doi:10.1177/082585970502100403PubMedGoogle ScholarCrossref
19.
Lattimer  L, Haywood  C  Jr, Lanzkron  S, Ratanawongsa  N, Bediako  SM, Beach  MC.  Problematic hospital experiences among adult patients with sickle cell disease.  J Health Care Poor Underserved. 2010;21(4):1114-1123.PubMedGoogle Scholar
20.
Haywood  C  Jr, Beach  MC, Lanzkron  S,  et al.  A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease.  J Natl Med Assoc. 2009;101(10):1022-1033. doi:10.1016/S0027-9684(15)31069-5PubMedGoogle ScholarCrossref
21.
National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease. Accessed April 2, 2019.
22.
Haider  SN, Tang  J, Osarogiagbon  RU.  Demographic and socio-economic features of a cohort of adult sickle cell disease patients.  Blood. 2009;114(22):4616. http://www.bloodjournal.org/content/114/22/4616. Accessed April 2, 2019. Google Scholar
23.
Master  S, Arnold  C, Davis  T, Mansour  RP.  Education, employment, social support and insurance coverage in adult patients with sickle cell disease.  Blood. 2016;128(22):4864. http://www.bloodjournal.org/content/128/22/4864. Accessed April 2, 2019. Google Scholar
24.
Weeks  J.  Early results of a pragmatic trial: report to a state agency on acupuncture for the underserved amid the opioid crisis.  J Altern Complement Med. 2017;23(12):901-902. doi:10.1089/acm.2017.29040.jjwPubMedGoogle ScholarCrossref
25.
Heyward  J, Jones  CM, Compton  WM,  et al.  Coverage of nonpharmacologic treatments for low back pain among US public and private insurers.  JAMA Netw Open. 2018;1(6):e183044-e183044. doi:10.1001/jamanetworkopen.2018.3044PubMedGoogle ScholarCrossref
26.
National Conference of State Legislatures. State medical marijuana laws. http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Published March 5, 2019. Accessed April 2, 2019.
27.
D’Souza  DC, Ranganathan  M.  Medical marijuana: is the cart before the horse?  JAMA. 2015;313(24):2431-2432. doi:10.1001/jama.2015.6407PubMedGoogle ScholarCrossref
28.
Hill  KP.  Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review.  JAMA. 2015;313(24):2474-2483. doi:10.1001/jama.2015.6199PubMedGoogle ScholarCrossref
29.
Devinsky  O, Marsh  E, Friedman  D,  et al.  Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.  Lancet Neurol. 2016;15(3):270-278. doi:10.1016/S1474-4422(15)00379-8PubMedGoogle ScholarCrossref
30.
Sun  X, Xu  CS, Chadha  N, Chen  A, Liu  J.  Marijuana for glaucoma: a recipe for disaster or treatment?  Yale J Biol Med. 2015;88(3):265-269.PubMedGoogle Scholar
31.
Darnall  BD, Humphreys  KN.  An experimental method for assessing whether marijuana use reduces opioid use in patients with chronic pain.  Addiction. 2018;113(8):1552-1553. doi:10.1111/add.14239PubMedGoogle ScholarCrossref
32.
Roberts  JD, Spodick  J, Cole  J, Bozzo  J, Curtis  S, Forray  A.  Marijuana use in adults living with sickle cell disease.  Cannabis Cannabinoid Res. 2018;3(1):162-165. doi:10.1089/can.2018.0001PubMedGoogle ScholarCrossref
33.
Jacobs H. Pain doctors: insurance companies won't cover the alternatives to opioids. Business Insider. https://www.businessinsider.com/doctors-insurance-companies-policies-opioid-use-2016-6. Published August 10, 2016. Accessed April 2, 2019.
34.
An Act To Establish a Pilot Project for Medicaid Reimbursement for Acupuncture Treatment of Substance Abuse Disorders. Sec. 1. 22-A MRSA §203, sub-§5. https://legislature.maine.gov/legis/bills/bills_128th/billtexts/HP014101.asp. Accessed April 2, 2019.
35.
Care Oregon. Benefit change for acupuncture. https://www.careoregon.org/docs/default-source/providers/updates/gn56_acupuncture_letter.pdf?sfvrsn=f9c5401e_0. Published March 15, 2018. Accessed April 2, 2019.
36.
Ohio Administrative Code 5160-8-51: Acupuncture services. http://codes.ohio.gov/oac/5160-8-51v1. Accessed April 2, 2019.
37.
National Academy for State Health Policy. Chronic pain management therapies in Medicaid: policy considerations for nonpharmacological alternatives to opioids. https://nashp.org/wp-content/uploads/2016/09/Pain-Brief.pdf. Accessed April 2, 2019.
38.
Lu  K, Cheng  MC, Ge  X,  et al.  A retrospective review of acupuncture use for the treatment of pain in sickle cell disease patients: descriptive analysis from a single institution.  Clin J Pain. 2014;30(9):825-830. doi:10.1097/AJP.0000000000000036PubMedGoogle ScholarCrossref
39.
Goodwin  JS, Kuo  Y-F, Brown  D, Juurlink  D, Raji  M.  Association of chronic opioid use with presidential voting patterns in US counties in 2016.  JAMA Netw Open. 2018;1(2):e180450-e180450. doi:10.1001/jamanetworkopen.2018.0450PubMedGoogle ScholarCrossref
40.
Henry J Kaiser Family Foundation. State health facts: opioid overdose deaths by race/ethnicity. https://www.kff.org/other/state-indicator/opioid-overdose-deaths-by-raceethnicity/?dataView=2&currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. Accessed April 2, 2019.
41.
Ruta  NS, Ballas  SK.  The opioid drug epidemic and sickle cell disease: guilt by association.  Pain Med. 2016;17(10):1793-1798. doi:10.1093/pm/pnw074PubMedGoogle ScholarCrossref
42.
Hausmann  LR, Gao  S, Lee  ES, Kwoh  CK.  Racial disparities in the monitoring of patients on chronic opioid therapy.  Pain. 2013;154(1):46-52. doi:10.1016/j.pain.2012.07.034PubMedGoogle ScholarCrossref
43.
Bediako  SM, Moffitt  KR.  Race and social attitudes about sickle cell disease.  Ethn Health. 2011;16(4-5):423-429. doi:10.1080/13557858.2011.552712PubMedGoogle ScholarCrossref
44.
Carroll  CP, Haywood  C  Jr, Fagan  P, Lanzkron  S.  The course and correlates of high hospital utilization in sickle cell disease: evidence from a large, urban Medicaid managed care organization.  Am J Hematol. 2009;84(10):666-670. doi:10.1002/ajh.21515PubMedGoogle ScholarCrossref
45.
Sop  D, Smith  W, Alsalman  A,  et al.  Survey of physician perspective towards management of pain for chronic conditions in the emergency department.  Mod Clin Med Res. 2017;1(3):55-70. doi:10.22606/mcmr.2017.13002Google ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Views 1,824
    Original Investigation
    Hematology
    May 24, 2019

    Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic: A Qualitative Study

    Author Affiliations
    • 1Division of Pediatric Hematology-Oncology-BMT, Emory University, Atlanta, Georgia
    • 2Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, Georgia
    • 3Now with the Department of Pediatric Hematology/Oncology/BMT, Emory University, Aflac Cancer and Blood Disorders Center, Atlanta, Georgia
    JAMA Netw Open. 2019;2(5):e194410. doi:10.1001/jamanetworkopen.2019.4410
    Key Points español 中文 (chinese)

    Question  Are concerns about the opioid epidemic in the United States and the heightened oversight and restrictions on prescribing opioids associated with changes in the management of acute and chronic pain for patients with sickle cell disease?

    Findings  This qualitative study interviewed 15 adults with sickle cell disease. Participants reported that they face increased barriers to the use of opioids for pain management, that their physicians exclusively focus on opioid dosage without establishing a multimodality pain management plan, and that they lack access to nonopioid therapies.

    Meaning  Adult patients with sickle cell disease should be included in establishing goals for managing pain and improving functionality using multimodality approaches.

    Abstract

    Importance  The hallmark of sickle cell disease (SCD) is vaso-occlusive pain that may be acute and episodic or may progress to chronic, persistent pain with unpredictable and disabling exacerbations. Patients with SCD rely on opioids almost exclusively for acute and chronic pain management.

    Objective  To understand how the current opioid epidemic and subsequent guidelines from the Centers for Disease Control and Prevention are associated with the management of acute and chronic pain for patients with SCD.

    Design, Setting, and Participants  Qualitative study using semistructured interview guides. Interviews 1 hour or longer were conducted over the telephone. Participants were adults (aged ≥18 years) diagnosed with SCD who experienced pain on 3 or more days per week recruited from national SCD conferences, symposiums, and 2 sickle cell clinics. Open coding analysis facilitated thematic analysis of interview transcripts. Data collection took place from May 2017 to June 2018.

    Main Outcomes and Measures  Participant perspective of any changes to their pain management associated with the 2016 guidelines from the Centers for Disease Control and Prevention.

    Results  The 15 adults interviewed had a median (range) age of 32 (21-52) years; 13 (87%) were female; and all were of African American race/ethnicity. Participants reported that recently their opioid prescriptions had become more restrictive, were more closely monitored, and were increasingly difficult to fill in pharmacies. Participants also described increased stigmatization about opioid use and that their medical care was being affected by the physician’s exclusive focus on reducing pain medication use. There was an emerging interest among adult patients in the consideration of the use of alternative therapies, including marijuana, to manage pain.

    Conclusions and Relevance  These findings suggest that from the perspective of adults living with SCD, the opioid epidemic may have negatively affected patients’ care by increasing barriers to opioids. Patients reported decreased opioid dosing, increased stigmatization regarding opioid use, physician preoccupation with opioid dosage interfering with comprehensive care, and lack of access to alternative therapies.

    Introduction

    Sickle cell disease (SCD) is a chronic multisystem disorder associated with vaso-occlusive pain and organ damage, leading to substantial morbidity, impaired health-related quality of life, substantial health care costs, and a high risk of premature mortality.1 Acute, episodic vaso-occlusive pain may progress to chronic persistent pain2 in more than a third of adults with SCD.2 Opioid analgesics are the mainstay for the management of acute and chronic pain in SCD.2

    In recent years, US federal and state governments have implemented comprehensive measures to address the alarming increase in deaths attributed to the abuse and overdose of prescription opioids.3-5 In an effort to improve communication between clinicians and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, the Centers for Disease Control and Prevention (CDC) published guidelines in 2016 for prescribing opioid therapy for chronic pain.3 Opioid prescriptions, which were declining prior to the publication of the CDC guidelines, have demonstrated a greater decline since its publication.6

    African American patients are more likely than white patients to be suspected of opioid abuse, subjected to more frequent urine screening, and referred to substance abuse services.7 In the United States, SCD predominantly affects African American individuals,8 and, thus, patients with SCD may face unique barriers to the management of pain with opioids.

    We sought to understand how the concerns about the opioid epidemic and the publication of the CDC guidelines are associated with changes in the management of acute and chronic pain for patients with SCD. Using rigorous qualitative research methods, we sought to obtain the perspective of adult patients with SCD on their experience of pain, their interaction with the health care system, and their perception of how the CDC guidelines affected the management of their acute and chronic pain.

    Methods

    We recruited individuals aged 18 years or older with SCD who were attending national conferences and 2 sickle cell clinics and from those who self-referred themselves to this study, which was approved by the Emory University institutional review board. Participants were enrolled following in-person or telephonic verbal consent. One investigator conducted semi-structured qualitative interviews with participants either in person or over the telephone. All participants received a $25 gift card for participation. Results are reported in compliance with the Consolidated Criteria for Reporting Qualitative Research (COREQ) reporting guideline.9

    The interview guide included prompts concerning diagnosis, childhood, family, school, relationships, work, life, pain, pain management, emergency department (ED) experiences, and the participant’s thoughts concerning the opioid epidemic and how it had influenced their care.

    All interviews were transcribed verbatim. We used NVivo software version 11 (QSR International) to perform the line-by-line coding.10 Coding concepts were derived from the participant responses and categories developed from these concepts with prevalence determined by content analysis, which quantifies the coding schemes and allows identification of the most prevalent of emerging patterns.11 Thematic analysis was then used as a descriptive analytical approach to illustrate the major themes.11

    To achieve in-depth analysis, we focused on a sample of 15 participants. In qualitative interviewing, a small sample allows for a more authentic account,12 that is, understanding how the participants’ point of view addresses our research question. The objective was to understand the constructed view of the participants’ social world rather than generalizing it to the population.13 Because rigorous analysis runs concurrently with data collection for concept-gathering studies, smaller sample sizes are advantageous for greater involvement of the investigator.14 In qualitative research, robust coding schemes can establish data saturation with concepts ceasing to offer any new perspective on the research question after 6 to 12 interviews.14

    As themes developed, investigators discussed and substantiated each with examples provided. The lead coder (C.B.S.) developed the initial coding scheme and shared the coding scheme with the second coder (D.R.). The second coder coded 20% of the sample. We then compared the number of occurrences of content and calculated a percentage of agreement. There was 90% agreement between the 2 coders identifying the same content coded.

    Results

    We approached 21 potential participants, all of whom initially agreed to participate and provided their contact information. Six individuals who had expressed initial interest were not reachable by telephone or email for consent. Twelve participants were recruited from conferences and 3 from clinics. Once they had consented, no participants dropped out of the study. Two participants whose interviews did not specifically address the opioid epidemic were recontacted for follow-up questions.

    We interviewed 15 adults (median [range] age, 32 [21-52] years; 13 [87%] female; all of African American race/ethnicity). Five were employed full time or part time and 10 received Social Security disability benefits. All participants self-reported that their genotype was HbSS, HbSC, and/or HbS-β-thalassemia. Participants were interviewed in person and over the telephone. Across these interview methods, there were no discernible differences in participant narrative. The median (range) length of the participant interviews was 52 minutes (range, 45 minutes to 1.5 hours).

    All participants reported pain on 3 or more days per week and had a current prescription for opioids to treat their pain. Regular prescriptions of opioids were started in 12 participants in childhood or adolescence and 3 in adulthood.

    Three themes emerged from the analysis. First, participants reported that recently their opioid prescriptions have become more restrictive, more closely monitored, and increasingly difficult to fill in pharmacies. Second, participants believed that their physician’s exclusive focus on reducing pain medication resulted in further stigmatization and decreased attention to patient’s overall medical care. Third, there was an emerging interest among adult patients in the consideration of the use of alternative therapies, including marijuana, to manage pain. In many cases, patients felt forced to pursue nonopioid approaches because of issues with access to opioids.

    Increasing Restrictions and Monitoring of Opioid Use

    Participants reported being under increasing pressure to sign a treatment agreement, despite, in some cases, having received opioids to treat pain for several years from the same practice. Overall, 10 participants (67%) currently had a signed agreement with their physicians for opioid prescriptions, 8 of them within the year prior to the interview.

    Participants understood that the primary objective of the treatment agreement was to ensure that patients do not sell their opioids or go “doctor shopping.” Participants indicated that while they had conversations with their physician about dependence on opioids and the need for reductions in their opioid prescriptions, they did not have conversations about comprehensive evaluation and management of pain, including the use of alternative therapies.

    The reduction in prescriptions resulted in participants rationing their pain medication and being unable to increase their dosage at the onset of a pain crisis or in the presence of a trigger for crisis such as cold weather.

    One participant stated, “When something stresses me out maybe they used to do every 2 weeks of getting my medication. Now it’s down to once a month or they [the physician] may say instead of third of the pills [30 pills], we’re only going to give you 15. So, it [the opioid epidemic] has definitely affected me personally and I hate that. Like, I know the wintertime is one of the worse times for me. This winter [state] had one of the worse winters we’ve had.”

    Frequently, participants described their treatment history with the phrase “used to” to convey that their regular clinician had recently changed their opioid prescription. Additional barriers included limits to the number of opioid prescriptions permissible by their health insurance company or their pharmacy stocking inadequate supplies of opioids. A participant stated, “There was some law…that had changed earlier this year, they wanted to ask my doctor questions on why I needed so much medicine. I have Medicaid.” Another participant stated, “I went to 10 pharmacies in 1 day to get an oxycodone prescription. They told me that they only order a certain amount.”

    Participants believed that opioid prescribing in the ED had also changed. Most participants lacked an established pain protocol for the ED and believed that health care professionals were not well versed in the management of SCD pain. One participant stated, “You have those [ED physicians] that they’re so limited in education that they’re skeptical about following your own protocol. It’s like my doctor wrote that protocol. You’re [ED physician] putting me in harm’s way, but of course they’re not familiar with the dosage you are on, things of that sort, so your safety becomes a prohibiting factor to them. There are specific protocols but they’ll ignore it.”

    In the ED, participants also reported having to negotiate for their usual dose of opioids. At times, a shortage of hydromorphone was cited as a reason for reducing the dosage or prescribing another opioid. One participant stated, “Many people that have sickle cell are allergic to morphine and they don’t have Dilaudid so now we have to play Russian roulette and take the morphine. I think it is the worst thing to ever happen, I think it is beyond cruel.”

    Participants suspected during the shortage of hydromorphone that the hospital staff was reserving the drug for patients with conditions other than SCD. For example, ED staff advised that they do not have hydromorphone in the ED; however, when the patient with SCD was hospitalized, hydromorphone was available.

    Heightened Stigma and Focus on Pain

    Participants observed that the preoccupation with monitoring and limiting prescriptions was preventing their physician from providing comprehensive care, including the management of pain and comprehensive care of their disease. One participant stated, “They just ask me what my pain is. They ask me how my pain is. You okay with just using morphine? Yes. Okay and that’s about it and they take my blood work. That’s all the conversation I have. I’ve never had any real in-depth conversation concerning pain management.”

    Participants believed they should have interactive conversations with their physician regarding disease management. Two younger participants reported that they were used to having these conversations with their pediatric hematologist, but they were less likely to occur with their adult hematologist.

    The preoccupation with opioid monitoring occurred in the ED as well, with ED physicians, instead of taking patients’ reported pain at face value, preferring to wait for blood work to determine whether the patients were actually “sickling.” Consequently, participants felt they continued to be stigmatized as drug seekers and attributed the stigma to 2 primary factors, lack of knowledge among ED physicians in the management of SCD pain and racial bias. Overall, participants expressed the most dissatisfaction with ED physicians’ lack of SCD-related knowledge. They felt that if the physician and staff knew how to treat SCD complications, then they would not question their complaints of pain and stigmatize them as drug seekers. One participant stated, “In pediatrics they teach us ‘know your numbers, know where you don’t do well, know what medications that you take.’ Like that’s supposed to be a help, but when we go in [the ED] as adults and we do that then it’s like ‘whoa we got a drug seeker here!’ Because I’m only here because I’m seeking drugs…, ‘you got a drug seeker!’”

    Using Alternative Therapies

    Participants use nonpharmacological approaches such as hot baths and warm compresses, meditation, reading, praying, music, and art to manage pain and reported interest in other nonpharmacological approaches, such as acupuncture and physical therapy. Frequently, these modalities were cost-prohibitive for individuals with Medicaid. One participant stated, “Yes, I really liked the acupuncture but the crazy thing; my insurance company would not pay for that. Now that’s the part that tripped me out because you guys, they [physicians] don’t want us on opioids like that but yet they’re not willing to pay for alternative medicine, you know. I can’t afford $120 every time I’m in pain [and] want to go get acupuncture.”

    Participants also volunteered that marijuana was the most common nonopioid pharmacological approach considered. Six participants reported they had tried or currently use marijuana, in varying frequency, to ease SCD chronic pain. Some participants who used marijuana did so owing to increased restrictions and overall difficulties maintaining opioid therapy. A participant stated, “Yes, the hydrocodone pills. Because once CVS got their first prescription there’s only just that 1 prescription and then I needed a refill or whatever [after taking public transportation to pharmacy]. I had to like go back to my clinic and tell them I need a refill. They have to send it upstairs [and] I had to take it up there myself. Then I have to take the [public transportation] and this paper back to CVS. Then CVS said they’re missing something so I had to go back to my clinic. Honestly, really and truly, I do not use my pain medicine [opioids]…I smoke [marijuana].” For this patient, marijuana offered the least restrictive alternative to manage pain.

    Other participants sought marijuana to avoid the adverse effects of opioid therapy. One participant stated, “They had me on 180 milligrams of oxycodone and 30 milligrams of methadone. That was my pain regimen at home every day. I went from a very social person to a very isolated person and I would sleep all the time. I told my family, my pastor, and friends I am really close to [about using marijuana]. I only vape when I am in pain or when I feel it so it is not an everyday thing for me. I won’t say I was able to replace all my medicine except for the muscle relaxer but no more opioids. As of right now, I’m not affected by the opioid epidemic because I took myself out of it.”

    Those not using marijuana cited concerns with how to gain access to medical marijuana and concerns with the unknown effects of the drug. A participant stated, “You can get medical marijuana in [home state] but the only problem is that it is going to be a hell of a time finding a doctor who’s going to write you a prescription for it.”

    While mostly used for pain, participants also reported that the drug eased their depression and anxiety. Participants also reported that marijuana provides relief without the opioid adverse effects of severe constipation and grogginess and may allow them to reduce or eliminate opioids altogether.

    The participants who were interested in learning more about using marijuana were worried about using the drug, especially without physician monitoring. Participants were familiar with the effects of long-term opioid use. Owing to the risk of acute chest syndrome, participants expressed concern about smoking marijuana.

    Discussion

    To our knowledge, this is the first investigation to use rigorous qualitative methods to examine the perspective of adult patients with SCD on the impact of the national opioid epidemic and the CDC guidelines on their care and experience in health care settings. In the view of the participants, this has led to decreased access to opioids, increasing stigmatization, and impaired delivery of care, all pushing them to seek alternatives with little guidance or support. Thus, patients experience systemic barriers to managing acute and chronic pain and receiving comprehensive care for their SCD. Participants in this study described how the physician’s lack of understanding about pain from SCD results in lack of sensitivity to patient’s pain, not involving the patient in decision making, and consequently undertreating pain. These findings are concordant with results of survey-based studies examining quality of life for adults living with SCD.15-20 That most participants who signed an agreement with their physician to maintain opioid therapy only did so in the last year and that they “used to” get more opioid prescriptions in the past suggests a recent change in their care. Thus, our study provides the patient perspective on how concerns about the opioid epidemic may have adversely affected the efforts of patients with SCD to seek medical care and pain management.

    The intended audience of the CDC guidelines is primary care physicians prescribing opioids for chronic pain or pain conditions lasting more than 3 months. For circumstances outside the scope of these guidelines, such as receiving care for SCD in an ED, the guidelines recommend that physicians refer to guidelines written specifically for these scenarios. The National Heart, Lung, and Blood Institute guidelines21 recommend that patients should receive multiple modalities of care and state that the goal of the opioid component of treatment is to manage pain while maintaining functionality.

    The CDC guidelines are intended to be voluntary and are not prescriptive.3 They are based on the assessment that there is a lack of evidence demonstrating the long-term benefits of opioids to treat chronic pain, that long-term opioid use is potentially harmful, and that there is some evidence of benefits of nonpharmacologic and nonopioid pharmacologic treatments compared with long-term opioid use. The guidelines recommend that clinicians should consider opioid therapy only if the expected benefits to both pain and function are anticipated to outweigh risks to the patients, and that if opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy. Furthermore, they recommend that before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and only continue opioid therapy if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety. This qualitative study did not provide any evidence that physicians were routinely involving patients in discussions of this type or are combining nonpharmacologic therapy and nonopioid pharmacologic therapy such as nonsteroidal anti-inflammatory drugs, anticonvulsants, and antidepressants. These findings underscore the need for further education of physicians about the intent of the CDC’s recommendations. Clinicians should engage patients in a dialogue to establish goals for pain relief and functionality, jointly identify what works and what does not, and, together, formulate a multimodality approach to pain management. For patients with SCD who receive Medicaid,22,23 there is limited access to nonpharmacological therapies because Medicaid may not cover these therapies.24,25

    Several participants viewed marijuana as a potential means of addressing pain without the adverse effects associated with opioids. Medical marijuana is currently legal in almost all US states, but possession remains a federal offense.26 Each state determines the medical conditions allowable and method of consumption for the drug, with only 4 states listing SCD as one of the approved indications. While clinical studies report moderate effectiveness of marijuana in the treatment of various chronic conditions,27-30 including chronic pain, where it may be opioid-sparing,31 there is little research on its effectiveness in treating SCD pain. Roberts et al32 reported that approximately 40% of participants with SCD report using marijuana. Participants in this study cited lack of access to, the unacceptable adverse effects of, and a desire to be free of opioids as reasons for considering the use of marijuana.

    Participants also considered physical therapy and acupuncture as potential treatments for managing pain, but access to these interventions may be limited by lack of coverage by Medicaid.33 In 4 states, Medicaid covers acupuncture for back pain and migraine, but no state covers this intervention for SCD.34-37 There are limited data available on the efficacy of acupuncture in the management of pain in SCD.38

    Individuals self-identifying as white non-Hispanic are more likely to be prescribed and engaged in long-term use of opioids compared with other racial/ethnic groups.39,40 Of the 16 000 deaths attributed to opioid overdose in 2013,41 only 10 occurred in patients with SCD.41 Nonetheless, racial minorities are more likely to be perceived as addicted to opioids and exhibiting drug-seeking behavior in the ED.42 Race may influence how health care professionals view and treat patients with SCD43 and their attitude toward patients’ accounts of intensity of pain.44 Participants in this study believed that their race was an influential factor in negative experiences in the ED and that physicians who were knowledgeable about SCD were less likely to exhibit racial bias toward patients with SCD.45

    Limitations

    There are several limitations to this study. Female patients were overrepresented in the sample. It is possible that a more representative sample could potentially reveal different themes. Participants were recruited from among the attendees at national sickle cell disease conferences and may have been more activated in regard to disease self-management, had access to more resources, and have been less representative of the general population of patients with SCD. Lacking access to participants’ medical records, the investigative team had no way to independently verify participants’ accounts of experience with opioids.

    Conclusions

    This study suggests that from the perspective of adult patients, the opioid epidemic may have negatively affected the care of patients with SCD by increasing barriers to care. Patients reported decreased access to opioids, increased stigmatization regarding opioid use, and physician preoccupation with opioid dosage without attention to multimodality care or alternative therapies. Further research is required to generate a better understanding of the mechanisms underlying the transition from acute episodic to chronic persistent pain in SCD and the management of chronic pain, including the use of nonopioid pharmacological and nonpharmacological approaches.

    Back to top
    Article Information

    Accepted for Publication: April 4, 2019.

    Published: May 24, 2019. doi:10.1001/jamanetworkopen.2019.4410

    Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Sinha CB et al. JAMA Network Open.

    Corresponding Author: Lakshmanan Krishnamurti, MD, Emory University, Department of Pediatric Hematology/Oncology/BMT, Aflac Cancer and Blood Disorders Center, 1405 Clifton Rd, Atlanta, GA 30322 (lkrishn@emory.edu).

    Author Contributions: Drs Sinha and Krishnamurti had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

    Concept and design: Sinha, Ross, Krishnamurti.

    Acquisition, analysis, or interpretation of data: Sinha, Bakshi, Krishnamurti.

    Drafting of the manuscript: Sinha, Ross, Krishnamurti.

    Critical revision of the manuscript for important intellectual content: All authors.

    Statistical analysis: Krishnamurti.

    Obtained funding: Krishnamurti.

    Administrative, technical, or material support: Ross, Krishnamurti.

    Supervision: Krishnamurti.

    Conflict of Interest Disclosures: Dr Bakshi reported grants from National Heart Lung and Blood Institute of the National Institutes of Health under Award K23HL140142 during the conduct of the study. No other disclosures were reported.

    Funding/Support: This study was funded by Patient-Centered Outcomes Research Institute grant CER-1211-4318EM to Dr Krishnamurti.

    Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

    Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

    References
    1.
    Platt  OS, Brambilla  DJ, Rosse  WF,  et al.  Mortality in sickle cell disease: life expectancy and risk factors for early death.  N Engl J Med. 1994;330(23):1639-1644. doi:10.1056/NEJM199406093302303PubMedGoogle ScholarCrossref
    2.
    Smith  WR.  Treating pain in sickle cell disease with opioids: clinical advances, ethical pitfalls.  J Law Med Ethics. 2014;42(2):139-146. doi:10.1111/jlme.12129PubMedGoogle ScholarCrossref
    3.
    Dowell  D, Haegerich  TM, Chou  R.  CDC guideline for prescribing opioids for chronic pain—United States, 2016.  JAMA. 2016;315(15):1624-1645. doi:10.1001/jama.2016.1464PubMedGoogle ScholarCrossref
    4.
    Cantrill  SV, Brown  MD, Carlisle  RJ,  et al; American College of Emergency Physicians Opioid Guideline Writing Panel.  Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department.  Ann Emerg Med. 2012;60(4):499-525. doi:10.1016/j.annemergmed.2012.06.013PubMedGoogle ScholarCrossref
    5.
    Johnson  K, Jones  C, Compton  W,  et al.  Federal response to the opioid crisis.  Curr HIV/AIDS Rep. 2018;15(4):293-301. doi:10.1007/s11904-018-0398-8PubMedGoogle ScholarCrossref
    6.
    Bohnert  ASB, Guy  GP  Jr, Losby  JL.  Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention’s 2016 opioid guideline.  Ann Intern Med. 2018;169(6):367-375. doi:10.7326/M18-1243PubMedGoogle ScholarCrossref
    7.
    Crowley-Matoka  M.  How to parse the protective, the punitive and the prejudicial in chronic opioid therapy?  Pain. 2013;154(1):5-6. doi:10.1016/j.pain.2012.10.013PubMedGoogle ScholarCrossref
    8.
    Brousseau  DCA, Panepinto  JA, Nimmer  M, Hoffmann  RG.  The number of people with sickle-cell disease in the United States: national and state estimates.  Am J Hematol. 2010;85(1):77-78.PubMedGoogle Scholar
    9.
    Tong  A, Sainsbury  P, Craig  J.  Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups.  Int J Qual Health Care. 2007;19(6):349-357. doi:10.1093/intqhc/mzm042PubMedGoogle ScholarCrossref
    10.
    Strauss  A, Corbin  J.  Basics of Qualitative Research Techniques. London, England: Sage Publications; 1998.
    11.
    Vaismoradi  M, Turunen  H, Bondas  T.  Content analysis and thematic analysis: implications for conducting a qualitative descriptive study.  Nurs Health Sci. 2013;15(3):398-405. doi:10.1111/nhs.12048PubMedGoogle ScholarCrossref
    12.
    Miller  J, Glassner  B. The ‘inside’ and the ’outside’: finding realities in interviews. In: Silverman  D, ed.  Qualitative Research: Theory, Method and Practice. London, England: Sage Publications; 1997:99-112.
    13.
    Holdstein  JA, Gubrium  JF. Active interviewing. In: Silverman  D, ed.  Qualitative Research: Theory, Method and Practice.  London, England: Sage Publications; 1997:113-129.
    14.
    Crouch  M, McKenzie  H.  The logic of small samples in interview-based qualitative research.  Soc Sci Inf (Paris). 2006;45(4):483-499. doi:10.1177/0539018406069584Google ScholarCrossref
    15.
    Treadwell  MJ, Hassell  K, Levine  R, Keller  S.  Adult sickle cell quality-of-life measurement information system (ASCQ-Me): conceptual model based on review of the literature and formative research.  Clin J Pain. 2014;30(10):902-914. doi:10.1097/AJP.0000000000000054PubMedGoogle ScholarCrossref
    16.
    Pack-Mabien  A, Labbe  E, Herbert  D, Haynes  J  Jr.  Nurses’ attitudes and practices in sickle cell pain management.  Appl Nurs Res. 2001;14(4):187-192. doi:10.1053/apnr.2001.26783PubMedGoogle ScholarCrossref
    17.
    Shapiro  BS, Benjamin  LJ, Payne  R, Heidrich  G.  Sickle cell-related pain: perceptions of medical practitioners.  J Pain Symptom Manage. 1997;14(3):168-174. doi:10.1016/S0885-3924(97)00019-5PubMedGoogle ScholarCrossref
    18.
    Labbé  E, Herbert  D, Haynes  J.  Physicians’ attitude and practices in sickle cell disease pain management.  J Palliat Care. 2005;21(4):246-251. doi:10.1177/082585970502100403PubMedGoogle ScholarCrossref
    19.
    Lattimer  L, Haywood  C  Jr, Lanzkron  S, Ratanawongsa  N, Bediako  SM, Beach  MC.  Problematic hospital experiences among adult patients with sickle cell disease.  J Health Care Poor Underserved. 2010;21(4):1114-1123.PubMedGoogle Scholar
    20.
    Haywood  C  Jr, Beach  MC, Lanzkron  S,  et al.  A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease.  J Natl Med Assoc. 2009;101(10):1022-1033. doi:10.1016/S0027-9684(15)31069-5PubMedGoogle ScholarCrossref
    21.
    National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease. Accessed April 2, 2019.
    22.
    Haider  SN, Tang  J, Osarogiagbon  RU.  Demographic and socio-economic features of a cohort of adult sickle cell disease patients.  Blood. 2009;114(22):4616. http://www.bloodjournal.org/content/114/22/4616. Accessed April 2, 2019. Google Scholar
    23.
    Master  S, Arnold  C, Davis  T, Mansour  RP.  Education, employment, social support and insurance coverage in adult patients with sickle cell disease.  Blood. 2016;128(22):4864. http://www.bloodjournal.org/content/128/22/4864. Accessed April 2, 2019. Google Scholar
    24.
    Weeks  J.  Early results of a pragmatic trial: report to a state agency on acupuncture for the underserved amid the opioid crisis.  J Altern Complement Med. 2017;23(12):901-902. doi:10.1089/acm.2017.29040.jjwPubMedGoogle ScholarCrossref
    25.
    Heyward  J, Jones  CM, Compton  WM,  et al.  Coverage of nonpharmacologic treatments for low back pain among US public and private insurers.  JAMA Netw Open. 2018;1(6):e183044-e183044. doi:10.1001/jamanetworkopen.2018.3044PubMedGoogle ScholarCrossref
    26.
    National Conference of State Legislatures. State medical marijuana laws. http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Published March 5, 2019. Accessed April 2, 2019.
    27.
    D’Souza  DC, Ranganathan  M.  Medical marijuana: is the cart before the horse?  JAMA. 2015;313(24):2431-2432. doi:10.1001/jama.2015.6407PubMedGoogle ScholarCrossref
    28.
    Hill  KP.  Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review.  JAMA. 2015;313(24):2474-2483. doi:10.1001/jama.2015.6199PubMedGoogle ScholarCrossref
    29.
    Devinsky  O, Marsh  E, Friedman  D,  et al.  Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.  Lancet Neurol. 2016;15(3):270-278. doi:10.1016/S1474-4422(15)00379-8PubMedGoogle ScholarCrossref
    30.
    Sun  X, Xu  CS, Chadha  N, Chen  A, Liu  J.  Marijuana for glaucoma: a recipe for disaster or treatment?  Yale J Biol Med. 2015;88(3):265-269.PubMedGoogle Scholar
    31.
    Darnall  BD, Humphreys  KN.  An experimental method for assessing whether marijuana use reduces opioid use in patients with chronic pain.  Addiction. 2018;113(8):1552-1553. doi:10.1111/add.14239PubMedGoogle ScholarCrossref
    32.
    Roberts  JD, Spodick  J, Cole  J, Bozzo  J, Curtis  S, Forray  A.  Marijuana use in adults living with sickle cell disease.  Cannabis Cannabinoid Res. 2018;3(1):162-165. doi:10.1089/can.2018.0001PubMedGoogle ScholarCrossref
    33.
    Jacobs H. Pain doctors: insurance companies won't cover the alternatives to opioids. Business Insider. https://www.businessinsider.com/doctors-insurance-companies-policies-opioid-use-2016-6. Published August 10, 2016. Accessed April 2, 2019.
    34.
    An Act To Establish a Pilot Project for Medicaid Reimbursement for Acupuncture Treatment of Substance Abuse Disorders. Sec. 1. 22-A MRSA §203, sub-§5. https://legislature.maine.gov/legis/bills/bills_128th/billtexts/HP014101.asp. Accessed April 2, 2019.
    35.
    Care Oregon. Benefit change for acupuncture. https://www.careoregon.org/docs/default-source/providers/updates/gn56_acupuncture_letter.pdf?sfvrsn=f9c5401e_0. Published March 15, 2018. Accessed April 2, 2019.
    36.
    Ohio Administrative Code 5160-8-51: Acupuncture services. http://codes.ohio.gov/oac/5160-8-51v1. Accessed April 2, 2019.
    37.
    National Academy for State Health Policy. Chronic pain management therapies in Medicaid: policy considerations for nonpharmacological alternatives to opioids. https://nashp.org/wp-content/uploads/2016/09/Pain-Brief.pdf. Accessed April 2, 2019.
    38.
    Lu  K, Cheng  MC, Ge  X,  et al.  A retrospective review of acupuncture use for the treatment of pain in sickle cell disease patients: descriptive analysis from a single institution.  Clin J Pain. 2014;30(9):825-830. doi:10.1097/AJP.0000000000000036PubMedGoogle ScholarCrossref
    39.
    Goodwin  JS, Kuo  Y-F, Brown  D, Juurlink  D, Raji  M.  Association of chronic opioid use with presidential voting patterns in US counties in 2016.  JAMA Netw Open. 2018;1(2):e180450-e180450. doi:10.1001/jamanetworkopen.2018.0450PubMedGoogle ScholarCrossref
    40.
    Henry J Kaiser Family Foundation. State health facts: opioid overdose deaths by race/ethnicity. https://www.kff.org/other/state-indicator/opioid-overdose-deaths-by-raceethnicity/?dataView=2&currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. Accessed April 2, 2019.
    41.
    Ruta  NS, Ballas  SK.  The opioid drug epidemic and sickle cell disease: guilt by association.  Pain Med. 2016;17(10):1793-1798. doi:10.1093/pm/pnw074PubMedGoogle ScholarCrossref
    42.
    Hausmann  LR, Gao  S, Lee  ES, Kwoh  CK.  Racial disparities in the monitoring of patients on chronic opioid therapy.  Pain. 2013;154(1):46-52. doi:10.1016/j.pain.2012.07.034PubMedGoogle ScholarCrossref
    43.
    Bediako  SM, Moffitt  KR.  Race and social attitudes about sickle cell disease.  Ethn Health. 2011;16(4-5):423-429. doi:10.1080/13557858.2011.552712PubMedGoogle ScholarCrossref
    44.
    Carroll  CP, Haywood  C  Jr, Fagan  P, Lanzkron  S.  The course and correlates of high hospital utilization in sickle cell disease: evidence from a large, urban Medicaid managed care organization.  Am J Hematol. 2009;84(10):666-670. doi:10.1002/ajh.21515PubMedGoogle ScholarCrossref
    45.
    Sop  D, Smith  W, Alsalman  A,  et al.  Survey of physician perspective towards management of pain for chronic conditions in the emergency department.  Mod Clin Med Res. 2017;1(3):55-70. doi:10.22606/mcmr.2017.13002Google ScholarCrossref
    ×